These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 30804405)

  • 61. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
    Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
    Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Ineffective erythropoiesis in myelodysplastic syndrome].
    Iwama A
    Rinsho Ketsueki; 2018; 59(6):793-797. PubMed ID: 29973461
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 64. SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS.
    Huang Y; Hale J; Wang Y; Li W; Zhang S; Zhang J; Zhao H; Guo X; Liu J; Yan H; Yazdanbakhsh K; Huang G; Hillyer CD; Mohandas N; Chen L; Sun L; An X
    J Hematol Oncol; 2018 Feb; 11(1):19. PubMed ID: 29433555
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
    Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
    Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.
    Duetz C; Westers TM; In 't Hout FEM; Cremers EMP; Alhan C; Venniker-Punt B; Visser-Wisselaar HA; Chitu DA; de Graaf AO; Smit L; Jansen JH; van de Loosdrecht AA
    Br J Haematol; 2021 May; 193(4):798-803. PubMed ID: 33765355
    [TBL] [Abstract][Full Text] [Related]  

  • 67.
    Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
    Blood; 2017 Aug; 130(7):881-890. PubMed ID: 28634182
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.
    Papaemmanuil E; Cazzola M; Boultwood J; Malcovati L; Vyas P; Bowen D; Pellagatti A; Wainscoat JS; Hellstrom-Lindberg E; Gambacorti-Passerini C; Godfrey AL; Rapado I; Cvejic A; Rance R; McGee C; Ellis P; Mudie LJ; Stephens PJ; McLaren S; Massie CE; Tarpey PS; Varela I; Nik-Zainal S; Davies HR; Shlien A; Jones D; Raine K; Hinton J; Butler AP; Teague JW; Baxter EJ; Score J; Galli A; Della Porta MG; Travaglino E; Groves M; Tauro S; Munshi NC; Anderson KC; El-Naggar A; Fischer A; Mustonen V; Warren AJ; Cross NC; Green AR; Futreal PA; Stratton MR; Campbell PJ;
    N Engl J Med; 2011 Oct; 365(15):1384-95. PubMed ID: 21995386
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
    Yoshimi A; Abdel-Wahab O
    Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
    [TBL] [Abstract][Full Text] [Related]  

  • 70. GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies.
    Benbarche S; Pineda JMB; Galvis LB; Biswas J; Liu B; Wang E; Zhang Q; Hogg SJ; Lyttle K; Dahi A; Lewis AM; Sarchi M; Rahman J; Fox N; Ai Y; Mehta S; Garippa R; Ortiz-Pacheco J; Li Z; Monetti M; Stanley RF; Doulatov S; Bradley RK; Abdel-Wahab O
    Mol Cell; 2024 May; 84(10):1886-1903.e10. PubMed ID: 38688280
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.
    Jin S; Su H; Tran NT; Song J; Lu SS; Li Y; Huang S; Abdel-Wahab O; Liu Y; Zhao X
    PLoS One; 2017; 12(5):e0175523. PubMed ID: 28545085
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.
    Spinello A; Borišek J; Malcovati L; Magistrato A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681880
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
    Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
    Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
    [TBL] [Abstract][Full Text] [Related]  

  • 74. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
    Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
    Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
    [No Abstract]   [Full Text] [Related]  

  • 76. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
    Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
    Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cancer-associated mutations in SF3B1 disrupt the interaction between SF3B1 and DDX42.
    Zhao B; Li Z; Qian R; Liu G; Fan M; Liang Z; Hu X; Wan Y
    J Biochem; 2022 Jul; 172(2):117-126. PubMed ID: 35652295
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
    Volpe VO; Al Ali N; Chan O; Padron E; Sallman DA; Kuykendall A; Sweet K; Lancet JE; Komrokji RS
    Br J Haematol; 2022 Aug; 198(4):713-720. PubMed ID: 35751140
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
    Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
    Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.
    Visconte V; Avishai N; Mahfouz R; Tabarroki A; Cowen J; Sharghi-Moshtaghin R; Hitomi M; Rogers HJ; Hasrouni E; Phillips J; Sekeres MA; Heuer AH; Saunthararajah Y; Barnard J; Tiu RV
    Leukemia; 2015 Jan; 29(1):188-95. PubMed ID: 24854990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.